APP and Alzheimer disease: Hierro-Bujalance, et al. also demonstrated empagliflozin to reduce vascular damage, limit cortical thinning, reduce neuronal loss, reduce microglial burden in the brain parenchyma, and improve cognitive impairment in a mixed murine model of Alzheimer’s disease and T2DM (db/db mice and APP/PS1xdb/db mice) [176].